Eszter Mild, Erzsébet Lázár, Judit-Beáta Köpeczi, Enikő Kakucs, Marius Găzdac, Annamária Pakucs, Cezara Tudor and István Benedek
. Pozotrigo M, Adel N, Landau L, et al. Factors impacting stem cell mobilizationfailure rate and efficiency in multiple myeloma in the area of novel therapies: experience at Memorial Sloan Kattering Cancer Center. Bone Marrow Transplantation . 2013;48:1033-1039.
9. Worel N, Rosskopf K, Neumeister P, et al. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a
Sebastian Giebel, Sylwia Oborska, Joanna Romejko-Jarosinska, Jarosław Dybko, Joanna Mańko, Joanna Sawczuk-Chabin, Agata Szymańska, Wojciech Legieć, Anna Czyż, Magdalena Maruszak, Maria Saduś-Wojciechowska, Joanna Drozd-Sokołowska, Paweł Steckiewicz, Anna Ejduk, Ewa Paszkiewicz-Kozik, Tomasz Ogórka, Michał Osowiecki, Łukasz Targoński and Michał Taszner
identify factors associated with the risk of mobilizationfailure. The first prognostic system was elaborated by Gruppo Italiano Trapianto di Midollo Osseo in 2012 [ 11 ]. More recently, Olivieri et al [ 12 ] built on real large representative data a score to “rule in” patients at very high risk for poor mobilizers before starting mobilization, allowing changes in clinical management, to avoid highly likely mobilizationfailure. Predicted poor mobilizer score included as risk factors: increasing age, diagnosis of NHL, positive bone marrow biopsy or cytopenias before
Szende Jakab, Erzsébet Lázár, István Benedek, Judit Beáta Köpeczi, Annamária Pakucs and István Benedek
therapy for multiple myeloma in actual clinical practice. Korean J Intern Med. 2016;31:809-819.
14. Kyle R, Rajkumar S. Treatment of Multiple Myeloma: A Comprehensive Review. Clin Lymphoma Myeloma . 2009;9:278-288.
15. Uy G, Rettig M, Cashen A. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Expert Opin Biol Ther . 2008;8:1797-1804.
16. Mehdizadeh M, Hajifathali A, Tabarraee M, et al. Plerixafor in the Treatment of Stem Cell MobilizationFailure; First Experience in Iran. Iran J Pharm Res . 2013;12:189-191.
Matevz Skerget, Barbara Skopec, Darja Zontar and Peter Cernelc
were excluded from further evaluation. All three were salvaged with plerixafor and successfully underwent AHSCT. No patient failed mobilization with cyclophosphamide. All transplanted patients successfully engrafted.
The use of cyclophosphamide mobilization in MM patients results in lower mobilizationfailure, higher stem cell yield and fewer collection procedures but at the cost of higher toxicity. 6 , 9 , 10 Furthermore, cyclophosphamide affects lymphocyte subpopulations possibly affecting the response after AHSCT. In our study, we prospectively